- Lupin will acquire all rights to two inhalation medicines – Brovana Inhalation Solution and Xopenex Inhalation Aerosol from Sunovion Pharmaceuticals Inc. for a cash consideration $75 million.
- While Brovana is used in the treatment of chronic bronchitis, Xopenex HFA is used in the prevention of bronchospasm in adults, adolescents and children aged 4 and above.
- The transactions are expected to be accretive to Lupin’s earnings in the first year itself and is likely to be completed over the next 2-3 weeks.Lupin earned 36 percent of its overall revenue in financial year 2022 from North America.
